ZTS — Zoetis Inc
Price when we picked it (Apr 6, 2026)
$118.08
Target: $156.00 (+32.1%)
P/E Ratio
19.6
P/E Forward
15.7
Dividend
1.7%
Market Cap
$52B
EPS
$5.94
Consensus
Moderate Buy
What they do
Zoetis is the largest company in the world focused solely on animal health. It develops and manufactures medicines, vaccines, diagnostics, and technologies for pets (dogs, cats) and livestock (cattle, pigs, poultry). Spun off from Pfizer in 2013, it inherited decades of pharmaceutical experience and a global distribution network.
Its top products include: Simparica Trio (the #1 antiparasitic, ~$1.5B franchise), Apoquel/Cytopoint (dermatology, $1.74B franchise), Librela/Solensia (arthritis pain, $568M), and a broad portfolio of vaccines and antibiotics for livestock.
Zoetis generates about 65% of its revenue from pets and about 35% from livestock, with operations in over 100 countries and 29 global manufacturing plants.
Why we like it
Zoetis is the clear leader in an industry benefiting from long-term trends: the 'humanization of pets,' where owners treat pets like family and spend on premium health care. It has a recurring revenue model—annual vaccines, monthly antiparasitics, chronic treatments.
At $118, ZTS trades at a price vs. profit of 15.7x—a significant discount compared to its historical average of about 30x. The stock fell about 28% from its peak ($172) due to the Librela controversy (side effects in dogs), but the fundamentals are strong: 38% operating margin, $2.3B in cash coming in, and 12 consecutive years of dividend growth.
Wall Street analysts expect a Moderate Buy with an average target of about $156 (32% upside). The pipeline includes 12 potential blockbuster candidates in oncology, kidney disease, and cardiology.
Key Risk
The FDA is investigating Librela (for dogs) and Solensia (for cats) due to reported neurological side effects—over 2,300 pet deaths have been reported. The arthritis franchise already fell 3% in 2025 with an 11% drop in Q4. If regulatory restrictions increase or veterinary trust erodes further, it could harm a key growth pillar and the brand's reputation.
Additional risks: a slowdown in pet spending if the economy worsens; growing competition in antiparasitics and dermatology; currency exposure (about 50% of revenue outside the US); and reliance on Librela/Simparica as growth drivers.
This is educational and informational content, not financial advice. Always consult a qualified financial advisor before making investment decisions.
Vectorial Data picked ZTS on Apr 6, 2026 at $118.08.
Full Research
Zoetis Inc (ZTS) — Complete Research
Price: $118.08 | P/E Forward: 15.7 | Div Yield: 1.7% | Market Cap: $52B
What is Zoetis?
Zoetis is the largest company in the world dedicated exclusively to animal health. Spun off from Pfizer in 2013, it develops and manufactures medicines, vaccines, diagnostics, and technologies for pets and livestock in over 100 countries with about $9.5B in annual revenue.
Main Products
| Product | Category | Revenue | Notes |
|---|---|---|---|
| Simparica Trio | Antiparasitic (fleas/ticks/worms) | ~$1.5B (franchise) | Crossed $1B in US sales; +12% operational |
| Apoquel | Dermatology (allergic itch) | Part of $1.74B | Oral tablet for dogs; blockbuster |
| Cytopoint | Dermatology (allergic itch) | Part of $1.74B | Injectable monoclonal antibody |
| Librela | Arthritis pain (dogs) | Part of $568M OA | Under FDA scrutiny for adverse effects |
| Solensia | Arthritis pain (cats) | Part of $568M OA | First mAb for feline pain |
| Draxxin | Anti-infective livestock | Key product | Leading antibiotic for cattle |
| Vaccines | Livestock and pets | Broad portfolio | Cattle, pigs, poultry, pets |
| Diagnostics | Point-of-care | Growing segment | Vetscan, reference labs |
Revenue split: ~65% pets, ~35% livestock.
Key Numbers 2025
| Metric | Value |
|---|---|
| Revenue | $9.5B (+6% organic) |
| Operating Margin | ~38% |
| EBITDA Margin | ~44.8% |
| Free Cash Flow | $2.3B |
| Adjusted EPS | $6.41 |
| Employees | ~14,100 |
| Countries | 100+ |
| Manufacturing Plants | 29 global |
Dividend — 12 Years of Growth
- Annual Dividend: $2.12/share ($0.53 quarterly)
- Yield: 1.7%
- Payout Ratio: ~33% (well covered)
- Growth: 12 consecutive years of increase
- 5-Year CAGR: ~20% annually
Why ZTS at These Prices
ZTS is trading at $118, 28% below its 52-week high ($172.23). The main cause: the Librela controversy. The FDA reported neurological side effects and over 2,300 pet deaths. But context matters:
- With over 21M doses distributed, the rate of adverse events is below "rare" according to the EMA
- Monthly sales are stabilizing
- Zoetis is already developing successors (Portela, Lenivia) for 2026
- Other pillars (Simparica +12%, Apoquel/Cytopoint stable) remain strong
Analyst Analysis
| Metric | Value |
|---|---|
| Consensus | Moderate Buy |
| Buy / Hold / Sell | 6 / 5 / 0 |
| Average Target | $156 |
| Target Range | $130 - $200 |
| Upside | +32.1% |
Growth Catalysts
- Pet Humanization — Pet health spending grows 6-8% annually globally
- Pipeline: 12 potential blockbuster candidates in oncology, chronic kidney disease, and cardiology ($5B+ TAM)
- Simparica continues gaining market share (+12% in 2025)
- Diagnostics — Integrated "diagnose-then-treat" platform
- Emerging Markets — China, Brazil, India with accelerating pet ownership
- New OA Products — Portela and Lenivia launching in 2026
Main Risks
- Librela/Solensia — FDA scrutiny, neurological side effects, 2,300+ reported deaths
- Pet Spending Slowdown — Recession could reduce vet visits
- Competition — Increasingly competitive antiparasitics and dermatology
- Currency Exposure — ~50% revenue outside the US
- Concentration — Dependence on Simparica and Librela as growth drivers
Current Valuation
| Metric | Value |
|---|---|
| Price | $118.08 |
| P/E Forward | 15.7x (vs historical ~30x) |
| Div Yield | 1.7% |
| 52-Week High | $172.23 |
| Current Drawdown | -28% from peak |
| Guidance 2026 Revenue | $9.8B - $10.0B |
| Guidance 2026 Adj EPS | $7.00 - $7.10 |
Conclusion
ZTS at $118 is an opportunity to buy the world leader in animal health at a price vs. profit of 15.7x—half its historical valuation. The Librela controversy created the discount, but the fundamentals (38% operating margin, $2.3B cash coming in, 12 years of dividend growth, robust pipeline) remain unchanged. With 32% upside according to analysts plus the growing dividend, the total expected return is about 34%.
Research date: Apr 6, 2026 | Next review: Oct 2026
This is not financial advice.
This is not financial advice. Consult a certified financial advisor.
The author may hold positions in the securities discussed.
Past performance does not guarantee future results.